Abstract

Familial hypercholesterolemia (FH) is an autosomal codominant, life-threatening inherited condition. FH is characterized by an increased blood level of low-density lipoprotein cholesterol (LDL-C). Patients with FH are at serious risk of developing premature atherosclerotic cardiovascular disease. Association of FH with genetic variants in three genes (APOB, LDLR, and PCSK9) is well established, however, the data related to mutation spectrum and prevalence of FH in Saudi population is largely missing. Here, we studied two Saudi families segregating FH in an autosomal dominant manner. All exons and intro-exons junctions of three candidate genes (APOB, LDLR, and PCSK9) were sequenced using Sanger approach. Data analysis identified variants in exon 14 (c.1853C>T; p.Ala618Val) and exon 29 (c.13013G>A; p.Ser4338Asn) of the APOB gene in both families. Both variants perfectly segregating with FH phenotype in families. The variant (c.13013G>A) is located in the well-established active site of apolipoprotein B, thus, it might influence the enzyme activity. In conclusion, we found homozygosity for variant in APOB in families segregating FH. This study expanded the mutational spectrum of APOB in FH. In addition, the present study provided additional evidence that supports the important involvement of apolipoprotein B dysregulation in Saudi FH patients.

Highlights

  • Familial hypercholesterolemia (FH) is known to segregate in an autosomal dominant manner in families

  • FH is characterized by a high level of low-density lipoprotein cholesterol in blood that may lead to increased risk of cardiovascular disease later in life (Chiou and Charng, 2016, Lee, 2017, Xiang et al, 2017)

  • Table 1 shows the lipid profiles of individuals studied of family (a), family (a) include 27 individuals enrolled in this survey, Out of them, just 7 individuals were known hypercholesterolemia

Read more

Summary

Introduction

Familial hypercholesterolemia (FH) is known to segregate in an autosomal dominant manner in families. FH is characterized by a high level of low-density lipoprotein cholesterol in blood that may lead to increased risk of cardiovascular disease later in life (Chiou and Charng, 2016, Lee, 2017, Xiang et al, 2017). FH patients may encounter premature coronary artery disease as well (Nohara, 2016). FH patients carrying heterozygous mutations have cholesterol level between 250 and 300 mg/dL and males develop disease between the age of 30 - 50 years while females develop the disease between the age of. 40 - 60 years (Kayıkçıoğlu and Tokgözoğlu, 2017). Genetic diagnosis and therapeutic intervention are necessary for the prevention of FH related complications.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call